RecruitingPhase 1Phase 2NCT06575426

A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus

A Phase I/IIa, Single Site, Open-Label, Ascending Dose Study to Evaluate the Safety and Efficacy of OPF-310 [Encapsulated Porcine Islet Cells for Xenotransplantation] in Subjects With Type 1 Diabetes Mellitus

Sponsor

Otsuka Pharmaceutical Factory, Inc.

Enrollment

13 participants

Start Date

Jun 10, 2025

Study Type

INTERVENTIONAL

Conditions

Metabolic Disease Diabetes Mellitus, Type 1 Type 1 Diabetes Type 1 Diabetes Mellitus Immune System Diseases Hypoglycemia Autoimmune Diseases Glucose Metabolism Disorders (Including Diabetes Mellitus)Type 1 Diabetes (T1D)Severe Hypoglycemia T1D T1DM T1DM - Type 1 Diabetes Mellitus Islet Cell Transplantation Xenotransplantation Hypoglycemic Episode Islet Transplantation in Diabetes Mellitus Type 1

Summary

This study is First In Human study for Encapsulated Porcine Islet Cells for Xenotransplantation (OPF-310). The purpose of this study to assess the safety, tolerability, and efficacy of OPF-310 transplantation and to define the recommended Phase 2 dose (RP2D) in adult subjects with unstable Type 1 Diabetes Mellitus (T1DM) and a level 3 (severe) hypoglycemic episode at least three times within the 1 year prior to enrollment despite treatment with a closed loop system (CLS) for at least 6 months.

Eligibility

Min Age: 35 YearsMax Age: 65 Years

Inclusion Criteria14

Subject must be aged 35 to 65 years of age inclusive, at the time of signing the informed consent.
Subject has an established diagnosis of type 1 diabetes mellitus (T1DM)(in accordance with the American Diabetes Association's criteria), with a minimum duration since diagnosis of 5 years.
If one of the following criteria (either a or b) applies:
Subject has unstable T1DM, not achieving adequate control after receiving CLS (CGM:Dexcom G6, insulin pump: Omnipod® 5 or t:slim X2) under care of a qualified diabetes team for at least 6 months prior to enrollment.
Subject has unstable T1DM, not achieving adequate control after receiving CLS (CGM:Dexcom G7, insulin pump: Omnipod® 5, t:slim X2, iLet Bionic Pancreas or The Tandem Mobi System) under care of a qualified diabetes team for at least 6 months prior to enrollment.
If one of the following criteria (either a, b or c) applies:
Subject has had a Level 3 (severe) hypoglycemic episode (defined as having cognitive impairment requiring external assistance for recovery) at least three times within the 1 year prior to enrollment recorded in the medical record or patient log.
Subject has had a Level 3 (severe) hypoglycemic episode at least once within the 1 year prior to enrollment and demonstrates a Clarke Score ≥4, assessed by trained study personnel. The SHE(s) and Clarke Score must be recorded in the medical record or patient log.
Subject has had TBR \>1% at glucose levels below 70mg/dL and demonstrates a Clarke Score≥4, assessed by trained study personnel. TBR data used for screening and Clarke score must be recorded in the medical record or patient log.
Subject has C-peptide \<0.3 ng/mL following a mixed meal tolerance test or undetectable fasting C-peptide.
Hemoglobin A1C (HbA1c) ≤ 9.0
Contraceptive use must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
Subject who can agree to cooperate with lifetime follow-up after transplantation.
Subject is capable of providing signed informed consent

Exclusion Criteria35

Previous history of insulin resistance (defined as an average insulin dose requirement ≥ 0.8 unit/kg/day for 1 week prior to enrollment).
Subject has latent autoimmune diabetes in adults (LADA), ketosis-prone (Flatbush) diabetes, or maturity onset diabetes of the young (MODY).
CRP ≥ 10 mg/L.
Clinically unstable thyroid disease (thyroid stimulating hormone (TSH)\< the lower limit of the normal range of TSH at the site.) Patients with subclinical hyperthyroidism can be rescreened once TSH levels normalize due to treatment or other factors. In addition, patients with transiently abnormal TSH levels may undergo rescreening only once during the screening period.
History of malignancies within the past 5 years, excluding basal and squamous cell carcinoma
Positive serologies or nucleic acid testing for human immunodeficiency virus (HIV), hepatitis C, and hepatitis B.
Active or untreated proliferative diabetic retinopathy. Subjects may be rescreened once they are successfully treated.
Serious comorbid conditions that are likely to affect participation in the study, including:
Within the last 12 months, peripheral vascular disease with previous amputation.
History of New York Heart Association (NYHA) class II, III or IV congestive heart failure (CHF) and/or chronic atrial fibrillation.
Chronic obstructive pulmonary disease (COPD) or asthma with previous hospitalization for decompensation; a requirement for mechanical ventilation at any stage; or long- term treatment with oral corticosteroids.
Macroalbuminuria (\> 300 mg albumin/gm creatinine).
Estimated glomerular filtration rate (eGFR) cut-off of \< 30 ml/min for all per Kidney Disease Improving Global Outcomes (KDOQI) and Kidney Disease Outcomes Quality Initiative (KDIGO) consensus.
Use of warfarin or other anticoagulant therapy (except aspirin), or prothrombin time and international normalized ratio (PT-INR) \> 1.5
Adrenal insufficiency being treated with corticosteroids
Previous pan-peritonitis
Previous cardiovascular or cerebrovascular disease. NOTE: For the purposes of this exclusion criterion, "previous cardiovascular disease" is defined as the presence of co-existing cardiac disease, characterized by any of the following conditions:
Recent myocardial infarction (within past one year), or
Angiographic evidence of non-correctable coronary artery disease, or
Evidence of ischemia on functional cardiac exam (with a stress echo test recommended for subjects with a history of ischemic disease), or
Heart failure \> NYHAII
Patients with hematopoietic stem cell abnormalities (e.g., aplastic anemia, myelodysplastic syndrome)
Patients who received a blood transfusion in the previous 90 days, are anticipated to undergo surgery during the 1-year study period that may require transfusion, or have donated blood within the previous 90 days.
Previous receipt of an organ, skin allograft, or other tissue transplant from an allogeneic human or animal donor.
Treatment with immunosuppressive medication.
Previous abdominal surgery, excluding uncomplicated appendectomy, cholecystectomy, exploratory laparoscopy and hernia repair performed prior to 12 weeks prior to enrollment.
Treatment with any hypoglycemic medication prescribed for glycemic control, other than insulin therapy.
Treatment with acetaminophen or hydroxycarbamide.
Use of any investigational products within 12 weeks of enrollment (before entering run-in) or 5 half-lives of the investigational product, whichever is greater.
Subject has history of allergy to antibiotics (Amphotericin B, Cefazolin, Ciprofloxacin, Gentamicin), which are used during manufacture of OPF-310.
Previous history of insulin allergy (including porcine insulin), pork product allergy or alginate/seaweed allergy.
Panel reactive antibodies (PRA) \> 80 %.
Active drug, substance or alcohol addiction.
Body mass index (BMI) \>27 kg/m2.
Any other condition that, in the opinion of the Investigator, may interfere with adherence to the study protocol, including dementia, psychiatric disorder, medical condition, or a history of non-adherence to appointments or treatments

Interventions

COMBINATION_PRODUCTOPF-310

Dose(Part1): 6,000 islet equivalents (IEQ)/kg or 12,000 islet equivalents (IEQ)/kg Dose(Part2): Recommended Phase II Dose(RP2D), which will be determined based on the data of Part1 * In Part1, three subjects will be enrolled into the first dosing cohort (Cohort 1: 6,000 IEQ/kg) and they will undergo safety monitoring. Three subjects in Cohort 2 will be dosed with 12,000 IEQ/kg and will undergo safety monitoring. * In Part2, 7 subjects will be enrolled into the Part 2 dose-expansion part.